Findings from Federal University of Santa Catarina in the Area of Diet and Nutrition Described (Oral fish oil positively influences nutritional-inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on ...)
By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Health and Medicine - Diet and Nutrition. According to news reporting out of Florianopolis, Brazil, by NewsRx editors, research stated, "Studies suggest that the ingestion of fish oil (FO), a source of the omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), can reduce the deleterious side-effects of chemotherapy. The aim of this randomised clinical trial was to evaluate the effect of supplementation with oral FO for 9 weeks on nutritional parameters and inflammatory nutritional risk in patients with haematological malignancies during the beginning of chemotherapy."
Financial support for this research came from National Counsel of Technological and Scientific Development (see also Health and Medicine - Diet and Nutrition).
Our news journalists obtained a quote from the research from the Federal University of Santa Catarina, "Twenty-two patients with leukaemia or lymphoma were randomised to the unsupplemented group (UG) (n=13) or supplemented group (SG) (n=9). SG received 2 g/day of fish oil for 9 weeks. Nutritional status, serum acute-phase proteins and plasma fatty acids were evaluated before (T0) and after (T1) the intervention period. Data were analysed using two models; model 1, comprising data from all patients included in the study, and model 2, comprising data from UG patients with no increase in the proportions of EPA and DHA in plasma and data from SG patients showing an at least 100% increase in plasma EPA and DHA. SG showed an increased plasma proportion of EPA and DHA in both models. In model 2, C-reactive protein (CRP) and CRP/albumin ratio showed larger reductions in the SG. Overall long-term survival in both models (465 days after the start of the chemotherapy) was higher in the group ingesting fish oil (p <0.05)."
According to the news editors, the research concluded: "These findings indicate an improved nutritional-inflammatory risk and potential effects on long-term survival in patients with haematological malignancies supplemented with FO during the beginning of chemotherapy."
For more information on this research see: Oral fish oil positively influences nutritional-inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on long-term survival: a randomised clinical trial. Journal of Human Nutrition & Dietetics, 2017;():. (Wiley-Blackwell - www.wiley.com/; Journal of Human Nutrition & Dietetics - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-277X)
Our news journalists report that additional information may be obtained by contacting T.R. Chagas, Graduate Program in Nutrition, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil. Additional authors for this research include D.S. Borges, P.F. de Oliveira, M.C. Mocellin, A.M. Barbosa, C.Q. Camargo, J.A. Del Moral, A. Poli, P.C. Calder, E.B. Trindade and E.A Nunes.
Keywords for this news article include: Brazil, Florianopolis, South America, Diet and Nutrition, Health and Medicine.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC